Abattis Bioceuticals Corp (OTCMKTS:ATTBF) is planning to introduce nutraceutical designed innovative product – Comfort through Vergence Naturals Ltd, its wholly owned subsidiary, for the treatment of inflammation and chronic pain.
Chief Executive Officer and President, Rob Abenante said over 100 million population in North America are suffering from inflammation as well as chronic pain. The lost productivity and cost of medical treatment are estimated at over $600 billion a year. The company is aiming to address this debilitating condition using Comfort.
According to The Nielsen Company, the market for OTC pain relief has increased to $4.2 billion in the year 2017 from $3.7 billion in the year 2014. The number of deaths due to the use of opioid and nonsteroidal anti-inflammatory drugs have increased considerably. Hence, the urgent need exists for providing safe and effective solutions to cure inflammation as well as chronic pain.
President of Medical Advisory Board of Abattis Bioceuticals, Dr. Brazos Minshew said the chronic pain is the result of the breakdown of internal systems in our body and the failure to produce endogenous chemicals. The pain management in the body works by producing endocannabinoids that bind to and activates CB1 and CB2 receptors to cope with the pain. The human body also produces endorphins, which interacts with the opiate receptors to minimize the pain.
If the ability of the body to produce endorphins and endocannabinoids is slowed down, the patients suffer from chronic pain. Comfort consists of Capsicum Annuum and Alpinia Galangal to release endorphin and activates endocannabinoid system to mitigate the chronic pain. The innovative pain relief product is developed using US FDA approved manufacturing practices. Comfort will be released on November 26, 2018.
Abattis Bioceuticals Corp Appoints a Corporate Secretary
Abattis Bioceuticals Corp has announced the appointment of corporate secretary – Nicole Breitinger. In her earlier stint, she rendered corporate services to a number of companies. She also operates her own business in the US and Canada.
Commenting on her appointment, Rob Abenante said Nicole will bring her special focus for the improvement of corporate governance.
The company is also continuing the development efforts of THC free, cannabinoid-rich, and hemp-infused craft beer in alliance with the Faculty Brewing Company.
Can B Corp (OTCMKTS: CANB) Signs Partnership To Market CBD Products and Releases Q1 2021 Results
Can B Corp (OTCMKTS: CANB) has entered a partnership with a company comprising World Champion Action Sports Athletes and Professional Hollywood Stuntmen to market the Can B Corp’s existing select CBD products and launch a new CBD brand at the end of the summer.
Can B enters a partnership for its CBD products
Notably, the Professional Hollywood Stuntmen group lists film credits include The Hunger Games, Breaking bad, Ant-Man, Twilight Saga, Fast & Furious 7, Jason Bourne, Mulan, The Expendables Better Call Saul, and others. Additionally, the group will commence marketing Can B Corp’s CBD products Slave 100& 200 mg and CryoGel Gold 500 mg.
Can B CEO Marco Alfonsi said, “This is a really exciting new partnership for our Company, as it provides a new untapped distribution channel for our manufacturing and production, which remains under-utilized. Our Lacey, Washington facility continues to have an excess capacity which we can use for new private label customers. This group of Professional Hollywood Stuntmen and World Champion Action Sports Athletes has great exposure and a wide social media following, which they will utilize to market and advertise the CBD products.”
Can B’s Q1 2021 revenue dropped 46%
Recently the company announced its Q1 2021, during which revenue was $306,940, a 46% YoY decline. The drop resulted from the pandemic’s impact leading to the halting of elective surgeries, which is the primary medical device revenue source for the company. Additionally, some distributors lost clients because of business closure impacting the company’s overall revenue. During the quarter, the company closed the acquisition of talent and assets from Botanical Biotech.
Alfonsi stated, “While we experienced a decline in our revenue due to Covid-19’s negative impact on markets we serve in elective surgeries and lost clients due to business closings of certain distributors, we have taken the time to maintain and strengthen our vertically integrated platform.”
The Valens Company Inc. (OTCMKTS: VLNCF) Signs Production and Distribution Deal with Harvest One
The Valens Company Inc. (OTCMKTS: VLNCF) has entered a two-year deal with Harvest One Cannabis Inc. as a provincial partner and white label manufacturer for cannabis-infused tropicals for LivReleif, its leading brand.
Harvest One launched LivRelief in 2020
Harvest One is a global marijuana infusion CPG operator that distributes high-quality self-care and wellness products, and it launched its leading cannabis-infused LivRelife products portfolio last year. Notably, since last year the products line has grown to be the number one cannabis-infused topicals selling brand in Ontario.
LivRelief is created through natural ingredients for deep penetration utilizing a novel transdermal delivery system that allows CBD to reach target areas. It is a growing cannabis-infused topical creams line that is available in their formats, including 1:1 formulation with 125mg THC and CBD, CBD only formulation with 250mg of CBD, and the recently launched extra strength CBD cream containing 750mg CBD. Currently, the products are available nationally through Medical Cannabis by Shoppers and at various private and provincial retailers.
Harvest One and Valens to expand distribution of LiRRelief
Through the partnership, The Valens and Harvest One will expand distribution and enhance customer awareness and brand loyalty nationwide. The first product shipments from Valens’ facilities will begin in fiscal Q4 2021.
Valens CEO Tyler Robson said, “The LivRelief cannabis-infused topical brand has established itself as a premium and reliable provider of cannabis-infused topicals with a leading-edge proprietary transdermal delivery system that took years of research, innovation, and dedication to develop. We are proud to manufacture these top-selling creams in partnership with Harvest One and provide both new and experienced consumers the comfort to engage with cannabis-infused topicals. Valens already manufactures the number one selling bath product in Ontario3 and now adds the number one selling cannabis-infused topical brand to its portfolio, making it a clear leader in both the topicals and health and wellness verticals in Canada.”
Vivo Cannabis Inc. (OTCMKTS: VVCIF) Receives Permit to Import Dried Medical Cannabis to Germany
Vivo Cannabis Inc. (OTCMKTS: VVCIF) has announced that it’s EU-GMP/GDP licensed affiliate Beacon Medical Germany GmbH has been granted an import permit by Germany’s Federal Institute for Drugs and Medical Devices. With the grant to the permit, the company can now import Canadian grown dried medical cannabis flower from Vivo’s ABcann Medicinal subsidiary’s GMP-certified Napanee, Ontario site into the EU.
Vivo taking steps to commercialize the product in Europe
Vivo holds cannabis licenses under the Cannabis ACT through its subsidiaries ABcann Medicinals Inc. and Canna Farms Limited.
Canna Farms Co-founder and VIVO CEO Ray Laflamme said, “We are making great strides towards our first commercialization of product in Europe. As a leader in medical cannabis in Canada and Australia, we are delighted by the opportunity to bring our Beacon Medical™ products to market and support the increasing demand from Germany’s more than 130,000 medical cannabis clients.”
The import permit received is issued on a shipment-by shipment basis. After receiving the export approval from Health Canada, the company will ship its first product in late Q3 or ear Q4, which will be offered under the Beacon medical brand.
Vivo Cannabis launched Canna Farms Brick Hash
The company recently launched Canna Farms Brick Hash, a high-quality, solventless, all-natural concentrate consumed as an edible through inhalation. Hashish is produced through resin extraction from cannabis and converting it into a solid form. Canna Farms Brick Hash is produced using modern tech and solvent-free extraction at the Hope facility. The novel process starts with blended Kief input from premium dried marijuana. Next, the hashish is slow-cooked and pressed, under pressure, cured, and wrapped in parchment to perfection for 30 days.
Laflamme said, “Our team has worked hard to perfect our process, and we’re very proud to bring to market another premium craft medical product catered to clients needing higher potency dosing.”